What do systematic reviews say?

Dermatan vs heparin

The review found no eligible studies for this question.

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dermatan vs heparin

The review found no eligible studies for this question.

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dermatan vs heparin

The review found no eligible studies for this question.

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Human activated protein C vs heparin

It is very uncertain whether human activated protein C changes adverse events compared with heparin (very low certainty).

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  RR 0.53 [0.05, 5.66]
  1 study · 107 participants
  Very low

Human activated protein C vs heparin

It is very uncertain whether human activated protein C changes bleeding compared with heparin (very low certainty).

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  RR 0.06 [0, 1.09]
  1 study · 132 participants
  Very low

Human activated protein C vs heparin

The review found no eligible studies for this question.

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Human activated protein C vs heparin

The review found no eligible studies for this question.

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Human activated protein C vs heparin

The review found no eligible studies for this question.

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human soluble thrombomodulin vs heparin

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 234 participants
  GRADE not reported

Recombinant human soluble thrombomodulin vs heparin

It is very uncertain whether recombinant human soluble thrombomodulin changes mortality from any cause (15‐day and 30‐day in‐hospital) compared with heparin (very low certainty).

• Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia 2015 · Cochrane Headline outcomes only
  RR 0.85 [0.54, 1.36]
  1 study · 227 participants
  Very low